CD44 and urinary bladder carcinoma: Our previous studies indicated that the monoclonal antibody BCMab1 recognized aberrantly glycosylated integrin α3 and could be used in the isolation of human bladder cancer stem cells (BCSCs) when combined with CD44 [31].